- Filament Health, a psychedelic drug discovery company, has announced the approval for their listing on the NEO exchange
Filament Health Corp., (NEO: FH) an exclusively-natural psychedelic drug discovery and extraction technology company, is pleased to announce it has received final approval to list its common shares on the Neo Exchange Inc. (the “NEO”) and will begin trading June 24, 2021 under the symbol NEO: FH.
Filament also completed the previously announced business combination between Filament Ventures Corp. (“Filament Ventures”) and 1287396 B.C. Ltd. (“396”) in accordance with an amalgamation agreement dated June 7, 2021 (the “Amalgamation Agreement”). Filament Ventures and 396 amalgamated under the Business Corporations Act (British Columbia) to continue as the Resulting Issuer.
“This is an important and exciting progression in Filament’s growth,” “We believe our differentiated platform is well-positioned to address the ongoing mental health crisis and that listing on the NEO will increase our access to capital and marketplace visibility.”
Benjamin Lightburn, Chief Executive Officer, Filament Health
As a result of the Transaction, the Filament has 164,689,369 common shares outstanding, and has reserved common shares for issuance of up to (i) 2,625,000 upon exercise of warrants; (ii) 250,200 upon exercise of broker compensation warrants; and (iii) 16,266,639 upon exercise of stock options.
The Resulting Issuer’s Board of Directors include Greg Mills (Chair), Ben Lightburn (CEO), Chris Wagner, Jon Conlin (Corporate Secretary) and Maureen O’Connell.
The Resulting Issuer’s Officers include Ben Lightburn (CEO), Tom Kineshanko (President), Warren Duncan (CFO), Lisa Ranken (COO) and Ryan Moss (Director of Research).
With deep experience in natural extraction technology commercialization, a robust and innovative IP portfolio, in-house GMP manufacturing, and a Health Canada psilocybin Dealer’s License, Filament has built the foundation to support a rapidly-scaling drug development pipeline. The company’s first drug candidates, IP-protected extract formulations of p. Cubensis mushrooms are poised to enter into Phase I and Phase II FDA clinical trials in the second half of 2021 – the first ever FDA-approved clinical trials conducted using natural psilocybin.
ABOUT FILAMENT HEALTH
Filament is an exclusively-natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer’s License. Filament is headquartered in Vancouver, British Columbia.